- |||||||||| Nanofitin / Affilogic
Journal: Development of versatile affinity-based system for one step purification process: case of Group A Streptococcus vaccine. (Pubmed Central) - Oct 12, 2022
The single-step affinity purification consistently delivered high purity product (above >90%) and improved performances compared to the current three-step process: reduced process time and footprint (3 to 1 step) and increased product yields (0.31 g vs 0.04g of SLO per kg of harvest broth). The custom affinity system herein described can potentially be applied to any biologic for which a specific Nanofitin is identified, thus establishing a platform with a strong impact on the manufacturing of vaccines and other biological targets.
- |||||||||| Nanofitin / Affilogic
Journal: Discovery of APL-1030, a Novel, High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation. (Pubmed Central) - Apr 30, 2022
APL-1030 is a novel, high-affinity inhibitor of primate C3-mediated complement activation developed from natural amino acids on the hyperthermophilic Nanofitin platform. Its properties may support novel drug candidates, enabling bifunctional moieties, gene therapy, and tissue-targeted C3 pharmacologics for diseases with high unmet need.
- |||||||||| Nanofitin / Affilogic
Journal, PD(L)-1 Biomarker, IO biomarker: Nanofitins targeting heat shock protein 110: an innovative immunotherapeutic modality in cancer. (Pubmed Central) - Sep 9, 2021
In this work, as an alternative to neutralizing antibodies, Nanofitins (scaffold ~7 kDa proteins) targeting HSP110 were isolated from the screening of a synthetic Nanofitin library, and their capacity to bind (immunoprecipitation, biolayer interferometry) and to inhibit HSP110 was analyzed in vitro and in vivo...Finally, we showed the complementarity between A-C2 and an anti-PD-L1 strategy in the in vivo and in ovo tumor models. Altogether, Nanofitins appear to be promising new immunotherapeutic lead compounds.
- |||||||||| Nanofitin / Affilogic
Journal: Gastrobodies are engineered antibody mimetics resilient to pepsin and hydrochloric acid. (Pubmed Central) - Sep 4, 2021
Two stable scaffold proteins (nanobody and nanofitin), previously developed to be protease-resistant, were completely digested in less than 10 min at 100-fold lower concentration of pepsin than found in the stomach...Anti-GTD binders retained high stability to acid, digestive proteases and heat. Gastrobodies show resilience to exceptionally harsh conditions, which should provide a foundation for targeting and modulating function within the GI tract.
|
